A new framework to efficiently screen drugs
Novel method to scale phenotypic drug screening drastically reduces the number of input samples, costs, and labor required to execute a screen.
Novel method to scale phenotypic drug screening drastically reduces the number of input samples, costs, and labor required to execute a screen.
Large multi-ring-containing molecules known as oligocyclotryptamines have never been produced in the lab until now.
By helping microbes withstand industrial processing, the method could make it easier to harness the benefits of microorganisms used as medicines and in agriculture.
Through academia and industry, Gevorg Grigoryan PhD ’07 says there is no right path — just the path that works for you.
A new gene-silencing tool shows promise as a future therapy against prion diseases and paves the way for new approaches to treating disease.
The program focused on AI in health care, drawing on Takeda’s R&D experience in drug development and MIT’s deep expertise in AI.
The SPARROW algorithm automatically identifies the best molecules to test as potential new medicines, given the vast number of factors affecting each choice.
SMART researchers find a cellular process called transfer ribonucleic acid (tRNA) modification influences the malaria parasite’s ability to develop resistance.
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
Immunai’s founders were researchers at MIT when they launched their company to help predict how patients will respond to new treatments.
MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments.
Using a DNA-based scaffold carrying viral proteins, researchers created a vaccine that provokes a strong antibody response against SARS-CoV-2.
Core-shell structures made of hydrogel could enable more efficient uptake in the body.
Thirteen new graduate student fellows will pursue exciting new paths of knowledge and discovery.
MIT spinout Kronos Bio, founded by Associate Professor Angela Koehler, studies the complex signaling networks of cancer cells to find new drug targets.